PCSK9: an emerging target for treatment of hypercholesterolemia
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Increased plasma low-density lipoprotein (LDL) cholesterol is a significant risk factor for cardiovascular disease. Plasma LDL-cholesterol is controlled through its uptake into cells upon binding the LDL receptor (LDLR). Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the LDLR and promotes its degradation, resulting in increased plasma LDL-cholesterol. Inhibiting the action of PCSK9 on the LDLR has emerged as a novel therapeutic target for hypercholesterolemia. AREAS COVERED: We briefly describe the identification and initial characterisation of PCSK9, before detailing the molecular mechanisms involved in its interaction with the LDLR. We highlight the potential sites for therapeutic intervention in this pathway and describe the current status of therapeutic approaches, including blocking antibodies, siRNA, antisense oligonucleotides and small-molecule inhibitors. The potential limitations of such approaches are also discussed. EXPERT OPINION: There is a wealth of evidence indicating that inhibition of PCSK9 is a highly desirable approach to combat hypercholesterolemia, with several agents in preclinical and clinical development. However, further research is required to fully understand the biological role of PCSK9 and whether its inhibition may have adverse effects in certain groups of patients, for example, those with liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“Unfortunately, it is often difficult to disrupt protein--protein interactions using such agents [73].”
BackgroundCohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · cited 1×
“Two nonsense mutations, Y142X and C679X, were found to be common in African Americans but rare in European Americans [39].”
BackgroundSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009) · Science · doi:10.1126/science.1168974 · Cited by 848
Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788 · cited 3×
“It is possible that PCSK9, which is known to bind the EGF-A module of the LDLR with high affinity at endosomal pH [16,48,49], disrupts normal Duff & Hooper”
BackgroundSecreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681 · cited 4×
“Multiple studies have demonstrated that the addition of conditioned media containing PCSK9 to untransfected HepG2 cells also causes a reduction in the number of surface LDLRs, confirming the activity of the protein after its secretion from the cell [28-30].”
BackgroundInfluentialDecreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
Rashid, S., Curtis, D. E., Garuti, R., Anderson, N. N., Bashmakov, Y., Ho, Y. K., Hammer, R. E., Moon, Y.-A., & Horton, J. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501652102 · Cited by 679
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517 · cited 1×
“The missense mutation A433T has been shown to lead to enhanced susceptibility to furin processing [40] while the commonly described R46 L variant has been found to have a reduced binding affinity for the LDLR [29,41-45].”
BackgroundStructure of the LDL Receptor Extracellular Domain at Endosomal pH
Rudenko, G., Henry, L., Henderson, K., Ichtchenko, K., Brown, M. S., Goldstein, J. L., & Deisenhofer, J. (2002) · Science · doi:10.1126/science.1078124 · Cited by 482 · cited 2×
“It is thought this event is required for ligand (LDL) release and receptor recycling (Figure 1) [52,53].”
BackgroundPoirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708098200 · Cited by 477 · cited 1×
“For example, PCSK9 has been reported to modulate the levels of the very-low density lipoprotein receptor (VLDLR) and apolipoprotein E receptor 2 (ApoER2) in cell culture systems [88], raising the possibility that it may influence other metabolic factors.”
BackgroundMaxwell, K. N., Fisher, E. A., & Breslow, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409736102 · Cited by 415
Davis, C. G., Goldstein, J. L., Südhof, T. C., Anderson, R. G. W., Russell, D. W., & Brown, M. S. (1987) · Nature · doi:10.1038/326760a0 · Cited by 411 · cited 1×
“It is thought this event is required for ligand (LDL) release and receptor recycling (Figure 1) [52,53].”
BackgroundZaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., et al. (2008) · Hepatology · doi:10.1002/hep.22354 · Cited by 404
The activation and physiological functions of the proprotein convertases
Seidah, N. G., Mayer, G., Zaid, A., Rousselet, E., Nassoury, N., Poirier, S., Essalmani, R., & Prat, A. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.01.030 · Cited by 314 · cited 1×
“The PCs are involved in the regulation of many cellular processes through the limited proteolysis of a wide range of proteins into their active/inactive forms [14].”
BackgroundEffect of mutations in the PCSK9 gene on the cell surface LDL receptors
Cameron, J., Holla, Ø. L., Ranheim, T., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl077 · Cited by 258 · cited 1×
“Multiple studies have demonstrated that the addition of conditioned media containing PCSK9 to untransfected HepG2 cells also causes a reduction in the number of surface LDLRs, confirming the activity of the protein after its secretion from the cell [28-30].”
BackgroundThe crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T., Shan, B., & Walker, N. P. C. (2007) · Structure · doi:10.1016/j.str.2007.04.004 · Cited by 251
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR
Nassoury, N., Blasiole, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., & Seidah, N. G. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00562.x · Cited by 248 · cited 1×
“intracellular compartment prior to its secretion [82-85].”
Berge, K. E., Ose, L., & Leren, T. P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204337.81286.1c · Cited by 236 · cited 1×
“The missense mutation A433T has been shown to lead to enhanced susceptibility to furin processing [40] while the commonly described R46 L variant has been found to have a reduced binding affinity for the LDLR [29,41-45].”
BackgroundA PCSK9 Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
Kathiresan, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707445 · Cited by 183 · cited 1×
“The missense mutation A433T has been shown to lead to enhanced susceptibility to furin processing [40] while the commonly described R46 L variant has been found to have a reduced binding affinity for the LDLR [29,41-45].”
BackgroundPCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., & Hedrick, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.106 · Cited by 180
Jonas, M. C., Costantini, C., & Puglielli, L. (2008) · The EMBO Reports · doi:10.1038/embor.2008.132 · Cited by 119
Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113035 · Cited by 107 · cited 8×
“Key to understanding the mechanism of PCSK9 action may stem from deciphering the role played by the CHRD. Experiments using truncated PCSK9 variants have shown that although PCSK9 lacking the CHRD binds to the LDLR, it does not target it for lysosomal degradation, indicating that it plays a key role in targeting the r…”
BackgroundInfluentialDuff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., & Hooper, N. M. (2009) · Biochemical Journal · doi:10.1042/bj20082407 · Cited by 99
Self-citationPCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Liu, M., Wu, G., Baysarowich, J., Kavana, M., Addona, G. H., Bierilo, K. K., Mudgett, J. S., Pavlovic, G., Sitlani, A., Renger, J. J., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006635 · Cited by 98 · cited 1×
“Interestingly, a subsequent report has presented data showing that the levels of BACE1 and amyloid-b were not significantly altered in Pcsk9 mice [90].”
BackgroundMaxwell, K. N., & Breslow, J. L. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000162321.31925.a3 · Cited by 82 · cited 1×
“Investigations also established that PCSK9 does not affect the synthesis or trafficking of the LDLR and that the activity of the proteasome is not required [27].”
BackgroundReynolds, C. A., Hong, M.-G., Eriksson, U. K., Blennow, K., Wiklund, F., Johansson, B., Malmberg, B., Berg, S., Alexeyenko, A., Grönberg, H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq079 · Cited by 57
Shibata, N., Ohnuma, T., Higashi, S., Higashi, M., Usui, C., Ohkubo, T., Watanabe, T., Kawashima, R., Kitajima, A., Ueki, A., et al. (2005) · Psychiatric Genetics · doi:10.1097/00041444-200512000-00004 · Cited by 28 · cited 1×
“Furthermore, there have been reports that there is no genetic association between PCSK9 and AD [91,92].”
Background
Cited by
The biology and therapeutic targeting of the proprotein convertases
Seidah, N. G., & Prat, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3699 · Cited by 759
TANG, Z., JIANG, L., PENG, J., REN, Z., WEI, D., WU, C., PAN, L., JIANG, Z., & LIU, L. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1072 · Cited by 208
Gadkar, K., Budha, N., Baruch, A., Davis, J. D., Fielder, P., & Ramanujan, S. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.47 · Cited by 48
Metadata
- Authors
- Duff, C. J., & Hooper, N. M.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2011-01-05
- Volume
- 15
- Issue
- 2
- Pages
- 157-168
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2110227562
- Cited by
- 49
- References
- 29
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.